The high attrition rates of novel drugs in clinical trials is a clear indication that current preclinical testing is failing to predict compounds that will reach the market. NeuCyte, is an early-stage biotechnology company focused on advancing the drug discovery process by using cell based target-identification and drug-discovery platforms. Our technology accelerates the lead drug identification and optimization process. NeuCyte’s unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity. NeuCyte’s all-star staff and scientific advisory board is comprised of some of the top stem cell biologists and neuroscientists in the world. The vast knowledge of our team gives us an unrivaled competitive advantage, which allows us to address the unmet needs of patients with neurological disorders.
Location: United States, California, San Carlos
Employees: 11-50
Total raised: $6.7M
Founded date: 2015
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.05.2018 | Series A | $6.7M | - |
Mentions in press and media 3
| Date | Title | Description |
| 02.03.2021 | WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. | |
| 01.12.2020 | WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc. | |
| 08.05.2018 | NeuCyte Closes $6.7M Series A Financing | NeuCyte, Inc., a Sunnyvale, Calif.-based neuroscience drug discovery company, closed a $6.7m Series A financing. The round, which brings total funding to date to over $8m, was led by initial investors, Cowin Venture and Leaguer Ventures. Th... |